Schering Corporation

Dendreon Corporation

Jinping L Mc Cormick

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

Anil K Saksena

Frank W Bennett

Raymond G Lovey

F George Njoroge

Zhaoning Zhu

Stephane L Bogen

Ashok Arasappan

Kevin X Chen

Yi-Tsung Liu

Odile Esther Levy

Patrick A Pinto

Tin-Yau Chan

Russell E Pike

Marguerita S Lim-Wilby

Edwin Jao

Haiyan Wang

Henry A Vaccaro

Tejal Parekh

Scott Jeffrey Kemp

Bama Santhanam

Susan Y Tamura

Srikanth Venkatraman

Yuhua Huang

Wanli Wu

Siska Hendrata

Jesse K Wong

Latha G Nair

Srinkanth Venkatraman

Viyyoor M Girijavallabhn

Marguerita Lim-Wilby

Edwin E Jao

Tejal N Parekh

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Peptides as NS3-serine protease inhibitors of hepatitis C virus

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Ribavirin derivatives represented by the formula II, pharmaceutical compositions containing them as well as methods of using the ribavirin derivatives represented by the formula II for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula IIare disclosed.

Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Growing community of inventors

Edison, NJ, United States of America

Jinping L Mc Cormick